{
  "docId": "019de070-3657-744f-8469-a4294fbedcbe",
  "docSlug": "17e3f38e05c3dcb59be9aebb9723e39c",
  "documentTitle": "Relay Therapeutics | IPO Presentation Deck | 25 slides",
  "authorId": "relay-therapeutics",
  "authorName": "Relay Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 25,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 15,
  "notes": "The slide uses a combination of a bar chart to show market opportunity and a Kaplan-Meier survival curve to show clinical efficacy, followed by a list of toxicity metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3657-744f-8469-a4294fbedcbe/19",
  "deckHref": "/decks/019de070-3657-744f-8469-a4294fbedcbe",
  "deckJsonHref": "/decks/019de070-3657-744f-8469-a4294fbedcbe.json",
  "deckAnchorHref": "/decks/019de070-3657-744f-8469-a4294fbedcbe#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.75,
        "y": 0.35
      },
      "kind": "callout",
      "text": "Progression-Free Survival (PFS) 11.0 vs. 5.7 months",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6355302a-6b46-4054-9d1a-5d507ff560ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Percentage of tumors with alteration by gene",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f14e3de-f3a3-4be6-87ad-e437d4b3c86a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Alpelisib Phase 3 SOLAR-1 trial Kaplan-Meier curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d182b81-400f-4adb-9d4e-56f94c8a70c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.5,
        "y": 0.65
      },
      "kind": "list",
      "text": "Significant toxicity metrics for Alpelisib",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f92b642-4ee5-4525-aa0a-91dd4a059b88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "PI3Kα – Mutant-Selective Drug Represents Significant Clinical Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee2bbfd6-eff3-47dc-8059-8b0c5c2a4c93",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "c1a86b43-628a-4125-96c5-e99feb1b0e55",
      "evidence": "Contrasts current suboptimal therapy with the clinical opportunity for a mutant-selective drug.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}